postoperative aspiration pneumonia among adults using glp-1 receptor agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus Mapping the effectiveness and risks
Description
A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss in a phase 2b clinical trial.
Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.
Advanced Metabolic Signaling Research
Your clinician determines clinical fit and the appropriate Microdose variant
COA included
